| 1 |
Non-Metastatic Triple Negative Breast Cancer with Neuroendocrine Differentiation: Survival Parameters |
2025 |
| 2 |
Predictive Factors for Site of Local and Systemic Recurrence in Breast Cancer Patients |
2025 |
| 3 |
Assessment of Response to Hormonal Therapy by Serum Ki-67 as a Biomarker in Non-metastatic Hormone Positive Breast Cancer |
2024 |
| 4 |
Prognostic Value of Erythropoietin-Producing Hepatocellular Receptor A2 (Epha2) Serum Marker in Colorectal Cancer |
2024 |
| 5 |
Prognostic Value of Vitamin D Receptor in Patients with Metastatic Colorectal Cancer Received Irinotecan-Based Systemic Treatment as a Second Line |
2024 |
| 6 |
The transcription factor ZEB-1 conveys chemoresistance in breast cancer |
2024 |
| 7 |
CD44 as a prognostic marker in early colorectal cancer: single center experience “South Egypt cancer institute”, Egypt |
2023 |
| 8 |
FOXP3 Expression as a Biomarker in Metastatic Colorectal Cancer Treated with Irinotecan-based Therapy |
2023 |
| 9 |
Tumor Lymphocytic Infiltration as a Prognostic Factor in Gastric Carcinoma |
2023 |
| 10 |
Assessment of the clinical value of red cell distribution width in patients with de novo hepatocellular carcinoma following HCV clearance with the direct-acting antiviral agents |
2021 |
